Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

3.19
BATS BZX Real-Time Price
As of 9:56am ET
 -0.09 / -2.74%
Today’s Change
1.51
Today|||52-Week Range
9.78
+56.37%
Year-to-Date
Why ImmunoGen, Inc. Skyrocketed Higher Today
Feb 27 / MotleyFool.com - Paid Partner Content
ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
Feb 20 / Zacks.com - Paid Partner Content
ImmunoGen, Inc.: Waiting to Move FORWARD
Feb 21 / MotleyFool.com - Paid Partner Content
ImmunoGen (IMGN) Reports Wider-than-Expected Loss
Feb 17 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close3.28
Today’s open3.38
Day’s range3.18 - 3.39
Volume31,256
Average volume (3 months)1,835,028
Market cap$286.3M
Dividend yield--
Data as of 9:56am ET, 02/28/2017

Growth & Valuation

Earnings growth (last year)-135.21%
Earnings growth (this year)--
Earnings growth (next 5 years)+15.00%
Revenue growth (last year)-29.86%
P/E ratioNM
Price/Sales4.46
Price/Book--

Competitors

 Today’s
change
Today’s
% change
EDGEEdge Therapeutics In...-0.17-1.70%
ADAPAdaptimmune Therapeu...-0.02-0.49%
RIGLRigel Pharmaceutical...-0.08-3.17%
SGMOSangamo Therapeutics...-0.35-8.14%
Data as of 9:55am ET, 02/28/2017

Financials

Next reporting dateMay 31, 2017
EPS forecast (this quarter)-$0.48
Annual revenue (last year)$60.0M
Annual profit (last year)-$144.8M
Net profit margin-241.35%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark J. Enyedy
Chief Financial Officer &
Executive Vice President
David B. Johnston
Corporate headquarters
Waltham, Massachusetts

Forecasts


Search for Jobs